Clinical Trials Logo

Clinical Trial Summary

This purpose of this study is to look at three commercially available ostomy barriers on peristomal (around the stoma) skin. Repeated barrier application and removal over years causes changes to the skin that the investigators wish to investigate. The primary objective is to measure peel force on normal skin and peel force on peristomal skin, with the intent of determining if differences occur. The study hypotheses is that no differences exist.


Clinical Trial Description

This is a single center, non-invasive exploratory study utilizing a sample of convenience. This study compares three commercially available barrier materials on peristomal skin and normal abdominal skin. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02003404
Study type Observational
Source Hollister Incorporated
Contact
Status Completed
Phase N/A
Start date November 2013
Completion date February 2014

See also
  Status Clinical Trial Phase
Completed NCT00362986 - Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer Phase 3
Completed NCT01416688 - S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
Completed NCT01347736 - Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection N/A
Terminated NCT00486213 - Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer Phase 3
Recruiting NCT00498992 - Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer N/A
Active, not recruiting NCT01393821 - Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab N/A
Completed NCT00438659 - Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Phase 3